Abstract

Objective:

By comparing viral sepsis caused by SARS CoV-2 with pneumosepsis caused by other pathogens, we aimed to compare the pathogen– host relationship, organ damage affecting the clinic, and similar and different features of the two types of sepsis.

Materials and Methods:

A total of 414 patients diagnosed with critical COVID-19 between 2019 and 2021 and 303 pneumosepsis cases that met the diagnostic criteria for sepsis-3 between 2016 and 2019 admitted to the Anesthesiology and Reanimation Intensive Care Unit (ICU) were retrospectively screened. The patient’s demographic data, mortality rates, length of stay in the intensive care unit, development of secondary organ dysfunction, presentation values of laboratory and mechanical ventilation, and changes within the 1-week follow-up were compared.

Results:

The SOFA scores were significantly higher in the COVID-19 sepsis group at presentation (8.2±2.9 vs.7.2±3.7; p<0.0001) and during follow-up (8.9 ± 4.9 vs. 7.8 ± 3.7; p=0.002). The mean age of the patients was 65.4 ± 17.2 years in the non-COVID-19 sepsis group and 57.9 ± 17.1 years in the COVID-19 sepsis group (p<0.0001). The number of days on mechanical ventilation was significantly higher in the COVID-19 sepsis group (p=0.018). Mortality was detected in 299 patients (41.7%) in total, with no significant difference being observed between the two groups (p=0.592).

Conclusion:

Despite the patient population having a lower mean age and fewer comorbidities, organ dysfunction was higher in COVID-19 sepsis patients during admission to the ICU and follow-up. While the pathogen causing sepsis can be brought under control with rapid diagnosis and appropriate antimicrobial treatment, organ damage cannot be controlled with appropriate antiviral treatment in COVID-19 sepsis. In COVID-19 sepsis, secondary organ damage may be more evident as a result of damage and immunomicrothrombosis, which causes high mortality and morbidity, the mechanism of which has not yet been fully elucidated.

Keywords: COVID-19 sepsis, SOFA score, pneumosepsis, organ damage

References

  1. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Intensive Care Med 2021;47:1181-247.
  2. Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units, 2017. JAMA 2020;32:1478-87.
  3. Weekly epidemiological update on COVID-19 - 22 March 2022.https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-march-2022 (accessed 2022-04-06).
  4. Mavi D, İnkaya A. COVID-19: Immunopathogenesis. Flora 2020;25:121-31.
  5. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and Viral Sepsis: Observations and Hypotheses. Lancet 2020;395:1517-20.
  6. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in Critically Ill Patients in the Seattle Region-Case Series. N Engl J Med 2020;382:2012-22.
  7. Wu M, Zou ZY, Chen YH, Wang CL, Feng YW, Liu ZF. Severe COVID-19-associated sepsis is different from classical sepsis induced by pulmonary infection with carbapenem-resistant klebsiella pneumonia (CrKP). Chin J Traumatol 2022;25:17-24.
  8. Karakike E, Giamarellos-Bourboulis EJ, Kyprianou M, Fleischmann-Struzek C, Pletz MW, Netea MG, et al. Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis. Crit Care Med 2021;49:2042-57.
  9. Cani E, Dwivedi DJ, Liaw KL, Fraser DD, Yeh CH, Martin C, et al. Immunothrombosis Biomarkers for Distinguishing Coronavirus Disease 2019 Patients From Noncoronavirus Disease Septic Patients With Pneumonia and for Predicting ICU Mortality. Crit Care Explor 2021;3:e0588.
  10. Arina P, Moro V, Baso B, Baxter-Derrington C, Singer M. Sepsis in severe COVID-19 is rarely septic shock: a retrospective single-centre cohort study. Br J Anaesth 2021;127:182-5.
  11. Dong X, Wang C, Liu X, Gao W, Bai X, Li Z. Lessons Learned Comparing Immune System Alterations of Bacterial Sepsis and SARS-CoV-2 Sepsis. Front Immunol 2020;11:598404.
  12. Yu J, Wang Y, Lin S, Jiang L, Sang L, Zheng X, et al. Severe COVID-19 has a distinct phenotype from bacterial sepsis: a retrospective cohort study in deceased patients. Ann Transl Med 2021;9:1054.
  13. Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine Elevation in Severe and Critical COVID-19: A Rapid Systematic Review, Meta-Analysis, and Comparison with Other Inflammatory Syndromes. Lancet Respir Med 2020;8:1233-44.
  14. Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and Outcomes of COVID-19 Hospitalisations: Systematic Review and Meta-Analysis. BMJ Evid Based Med 2021;26:107-8.
  15. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal Liver Function Tests. J Hepatol 2020;73:566-74.
  16. Rasch S, Herner A, Schmid RM, Huber W, Lahmer T. High lipasemia is frequent in Covid-19 associated acute respiratory distress syndrome. Pancreatology 2021;21:306-11.
  17. Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol 2020;18:2128-30.
  18. Tsonas AM, Botta M, Serpa Neto A, Horn J, Paulus F, Schultz MJ. Ventilation management in acute respiratory failure related to COVID-19 versus ARDS from another origin - a descriptive narrative review. Expert Rev Respir Med 2021;15:1013-23.
  19. Mahjoub Y, Rodenstein DO, Jounieaux V. Severe Covid-19 disease: rather AVDS than ARDS? Crit Care. 2020;24:327.
  20. Jounieaux V, Basille D, Abou-Arab O, Guillaumont MP, Andrejak C, Mahjoub Y, et al. Pure SARS-CoV-2 Related AVDS (Acute Vascular Distress Syndrome). BMC Infect Dis 2021;21:122.
  21. Diamond M, Peniston HL, Sanghavi D, Mahapatra S. Acute Respiratory Distress Syndrome. In StatPearls; StatPearls Publishing: Treasure Island (FL) 2022.
  22. Remy KE, Mazer M, Striker DA, Ellebedy AH, Walton AH, Unsinger J, et al. Severe Immunosuppression and Not a Cytokine Storm Characterizes COVID-19 Infections. JCI Insight 2020;5:140329.
  23. Grigorescu BL, Săplăcan I, Bordea IR, Petrisor M, Coman O, Puiac CI, et al. Endogenous Carboxyhemoglobin Level Variation in COVID-19 and Bacterial Sepsis: A Novel Approach? Microorganisms 2022;10:305.
  24. Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med 2020;46:1105-8.
  25. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature 2020;579:270-3.
  26. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631-7.
  27. Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, et al. CD209L (L-SIGN) Is a Receptor for Severe Acute Respiratory Syndrome Coronavirus. Proc Natl Acad Sci U S A 2004;101:15748-53.
  28. Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-NCoV Infection. bioRxiv February 4, 2020.http://doi.org/10.1101/2020.02.03.931766
  29. World Health Organization. Global Report on the Epidemiology and Burden of Sepsis: Current Evidence, Identifying Gaps and Future Directions; World Health Organization: Geneva, 2020.

How to cite?

1.
Ekşi ÖM, Çukurova Z, Sabaz MS, Aşar S, Tekdöş Şeker Y, Pektaş Y, et al. Could SARS-CoV-2 Sepsis Be a Different Phenotype of Sepsis? COVID-19 Pneumosepsis with Its Similarities and Differences. Turk J Intensive Care. 2023;22(2):132-143. https://doi.org/10.4274/tybd.galenos.2023.27146